N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin...

Details N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin... N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin...

2011-01-25

2011-01-25

Spivack, Phyllis G. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07875648

ABSTRACT:
The invention relates to a method of treating muscular dystrophy, such as a muscular dystrophy or myopathy resulting from mutations in genes encoding collagen VI, in a mammal. The method involves administering of a compound of the formula (I)or a pharmaceutically acceptable addition salt thereof to the mammal.

REFERENCES:
patent: 5780244 (1998-07-01), Engvall et al.
patent: 5780500 (1998-07-01), Betschart et al.
patent: 5780501 (1998-07-01), Betschart et al.
patent: 5863743 (1999-01-01), Campbell et al.
patent: 7078379 (2006-07-01), Rüegg
patent: WO 2007/022951 (2007-03-01), None
patent: WO 97/45422 (2007-12-01), None
Andringa et al.,Neurobiology of Disease, 14: 205-217 (2003).
Muck-Seler et al.,Current Drugs, 3(5): 530-535 (2000).
McGowan et al.,Microscopy Research and Technique, 51: 262-279 (2000).
Urtizberea,European Neurology, 43: 127-132 (2000).
Waldmeier et al.,Naunyn-Schmiedeberg's Arch Pharmacol, 362: 526-537 (2000).

Affiliated with

Also associated with

Rating

N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(dibenz(b,f)oxepin-10-ylmethyl)-N-methyl-N-prop-2-ynylamin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2655315